Surveillance of Clinical Isolates of Respiratory Syncytial Virus for Palivizumab (Synagis)–Resistant Mutants

Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in highrisk infa...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2004-09, Vol.190 (5), p.975-978
Main Authors: DeVincenzo, John P., Hall, Caroline B., Kimberlin, David W., Sánchez, Pablo J., Rodriguez, William J., Jantausch, Barbara A., Corey, Lawrence, Kahn, Jeffrey S., Englund, Janet A., Suzich, JoAnn A., Palmer-Hill, Frances J., Branco, Luis, Johnson, Syd, Patel, Nita K., Piazza, Franco M.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Biological and medical sciences
Cell Line
Children
Disease risk
Drug Resistance, Viral
Epitopes
Fluorescent Antibody Technique
Fundamental and applied biological sciences. Psychology
Heart diseases
Hospitalization
Human respiratory syncytial virus
Humans
Infant
Infectious diseases
Medical sciences
Microbial Sensitivity Tests
Microbiology
Miscellaneous
Monoclonal antibodies
Mutation
Neutralization Tests
Palivizumab
Preventive medicine
Pulmonary heart disease
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - epidemiology
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Infections - virology
Respiratory Syncytial Virus, Human - drug effects
Respiratory syncytial viruses
Virology
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in highrisk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from activepalivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.
ISSN:0022-1899
1537-6613
DOI:10.1086/423213